Similarly, the combinational therapy of BET inhibitors and other DNA damage-targeting agents has been applied to other preclinical cancer models, including pancreatic ductal adenocarcinoma [65], ovarian cancer [68], Myc-induced lymphoma cells [69], or melanoma [70]. This evidence concerns the gene DNER and pancreatic ductal adenocarcinoma.